¶ Fertility Preservation and Ovarian Reserve
| Indication | Elective and Medical Fertility Preservation, Ovarian Reserve Assessment [^11][^16][^17][^18] |
| Access | Clinical Referral (Reproductive Endocrinology & Infertility Specialists) [^10][^11] |
| Diagnostic Criteria | Clinically assessed via biochemical and sonographic markers of ovarian reserve [^16][^17][^18] |
| Safety Profile | Moderate (Controlled Ovarian Stimulation risks, Ovarian Hyperstimulation Syndrome) [^19][^20][^56] |
| Key Markers | Anti-Müllerian Hormone (AMH), Antral Follicle Count (AFC) [^16][^17][^18] |
| Est. Cost | Substantial; high out-of-pocket costs represent major barriers [^10][^15] |
Ovarian reserve assessment and fertility preservation technologies represent a major advancement in reproductive medicine, offering a highly validated methodology to quantify the remaining oocyte pool and safeguard future reproductive potential [1][2][3][4]. Evaluating ovarian reserve relies primarily on endocrine and sonographic markers, which guide the personalization of controlled ovarian stimulation (COS) protocols to optimize oocyte yield and clinical safety [2:1][3:1][4:1]. General ovarian reserve testing and elective (planned) fertility preservation are governed by reproductive medicine guidelines, such as those from the American Society for Reproductive Medicine (ASRM) [2:2]. In contrast, the American Society for Clinical Oncology (ASCO) establishes clinical guidelines strictly focused on patients undergoing cancer treatment (medical oncofertility) before receiving gonadotoxic therapies [1:1][5][6].
Figure 1: A professional clinical embryology laboratory equipped with high-precision microscopy and sterile laminar flow hoods for oocyte and embryo processing.
¶ At a Glance
¶ Key Points
- Ovarian Reserve: Represents the quantity of oocytes remaining, which declines progressively over a female's reproductive lifespan, resulting in lower live birth rates as maternal age advances [7][2:3].
- Cryopreservation Options: Vitrification of oocytes or embryos is the clinical standard of care, offering high post-thaw survival and clinical success rates compared to obsolete slow-freezing methods [8][9][10].
- Clinical Consensus: Prominent oncology clinical guidelines, such as those from the American Society for Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN), emphasize early, patient-centered discussions about fertility risks and preservation options before patients undergo gonadotoxic cancer treatments [1:2][5:1][11].
¶ Safety "Traffic Light"
- Critical Contraindications: Patient selection and the feasibility of controlled ovarian stimulation or tissue cryopreservation are determined by individual clinical factors, including the type of cancer, treatment urgency, patient age, and overall medical condition [12][1:3][13].
- Timing & Safety: Standard fertility preservation procedures must not significantly delay the initiation of necessary gonadotoxic cancer treatments [12:1][1:4].
- Risk Mitigation: The selection of specific stimulation protocols and starting gonadotropin doses must be individualized to minimize clinical risks (such as Ovarian Hyperstimulation Syndrome) in patients undergoing controlled ovarian stimulation [14][15][16].
¶ Protocol Card / Quick Reference
- Controlled Ovarian Stimulation (COS):
- Ovarian Reserve Assessment: Biomarkers such as Anti-Müllerian Hormone (AMH) and Antral Follicle Count (AFC) are utilized clinically to estimate expected ovarian response and guide the selection of gonadotropin doses [14:1][15:1].
- Stimulation Regimen: COS involves the administration of exogenous gonadotropins (such as follicle-stimulating hormone) to induce the development of multiple mature follicles [15:2][17].
- Oocyte Retrieval: Mature oocytes are harvested surgically during the retrieval procedure following controlled ovarian stimulation [2:4][4:2].
- Cryopreservation: Mature oocytes are cryopreserved immediately via vitrification [8:1][9:1], or fertilized with partner or donor sperm to create embryos for cryopreservation [18][9:2].
¶ Bottom Line
Vitrified oocytes and cryopreserved embryos provide highly effective, long-term options to preserve reproductive potential [1:5][8:2][9:3]. However, because ovarian reserve markers exclusively measure oocyte quantity rather than oocyte quality (which is strictly age-dependent), clinicians must emphasize that a normal AMH/AFC is not a guarantee of future live birth, nor does a low AMH/AFC in a young patient indicate infertility [7:1][2:5].
¶ What is Ovarian Reserve & Ovarian Aging?
¶ Pathophysiological Overview of Reproductive Aging
In clinical practice, a female's ovarian reserve refers to the size of the remaining follicle pool [2:6]. Unlike males, who undergo continuous spermatogenesis throughout post-pubertal life, the total quantity of follicles in a female is finite, established during fetal development, and naturally declines with increasing reproductive age [2:7][3:2]. This progressive, age-dependent decline in follicle quantity is accompanied by a concurrent decline in oocyte quality, leading to lower live birth rates as maternal age advances [7:2][2:8][3:3][4:3].
Evaluating a patient's ovarian reserve relies on biochemical and biophysical markers, which serve as surrogate measures for the remaining follicle pool [2:9][3:4][4:4]. Clinicians utilize these markers primarily to predict oocyte yield following controlled ovarian stimulation, helping to tailor starting gonadotropin doses and select appropriate stimulation protocols [2:10][3:5][4:5][14:2][15:3].
- Anti-Müllerian Hormone (AMH): AMH is a serum biomarker secreted by small growing follicles, making it a highly validated marker of oocyte quantity [2:11][3:6][4:6].
- Antral Follicle Count (AFC): AFC is a sonographic marker representing the number of antral follicles visualized in both ovaries via transvaginal ultrasound [2:12][3:7]. It serves as a direct biophysical measure of the responsive follicle pool [2:13][3:8].
¶ Chronological Age vs. Biological Ovarian Reserve
A fundamental concept in reproductive endocrinology is the distinction between chronological age and biological ovarian reserve [7:3][2:14]:
- Chronological Age (Primary Determinant of Quality): Chronological age is the single most reliable predictor of oocyte quality, which refers to the chromosomal normalcy (euploidy) and developmental competence of the gamete [7:4]. Fecundity declines naturally with age primarily due to declines in oocyte quality, leading to lower live birth rates particularly after age 35, highlighting that chronological age remains the primary driver of reproductive success [7:5][2:15].
- Biological Ovarian Reserve (Primary Determinant of Quantity): Ovarian reserve reflects the quantitative size of the remaining follicle pool [2:16]. While highly correlated with age on a population level, there is wide individual variation in the rate of follicle depletion [2:17]. A young patient may exhibit a prematurely diminished ovarian reserve (DOR) due to genetic factors such as FMR1 gene mutations [19], environmental exposures like endocrine-disrupting phthalates [20], or surgical interventions [12:2][21]. Crucially, while a young patient with DOR has fewer follicles (reduced oocyte quantity), their reproductive potential remains primarily driven by their young chronological age, as ovarian reserve markers are poor predictors of reproductive success and do not reflect oocyte health or quality [2:18][3:9][4:7].
¶ Ovarian Reserve Testing & Limitations
Evaluating a patient's ovarian reserve involves a systematic assessment of biochemical and biophysical markers [2:19][3:10][4:8]. These tests serve as surrogate measures for the size of the resting follicle pool and are primarily utilized to estimate response to controlled ovarian stimulation [2:20][3:11][4:9].
¶ Clinical Markers
¶ Anti-Müllerian Hormone (AMH)
Anti-Müllerian Hormone (AMH) is a serum biomarker secreted by small growing follicles that serves as a highly validated clinical marker to estimate ovarian reserve [2:21][3:12][4:10].
- Age-Dependent Decline: AMH levels decline progressively with age, serving as a reliable indicator of the shrinking follicle pool [7:6][2:22][3:13][4:11].
- Exogenous Suppression: Clinicians must be aware that exogenous hormones can temporarily suppress serum AMH levels, which should be considered during clinical interpretation [4:12].
- Environmental Exposures: Emerging cohort studies demonstrate that higher exposure to specific endocrine disruptors (such as phthalate metabolites including mIBP, mEHHP, mEOHP, and mBzBP) is associated with accelerated depletion of the ovarian reserve and lower overall serum AMH levels in women of reproductive age [20:1].
¶ Antral Follicle Count (AFC)
Antral Follicle Count (AFC) is a sonographic marker that measures the number of antral follicles visualized in both ovaries via transvaginal ultrasound [2:23][3:14].
- Clinical Utility: It serves as a direct, real-time biophysical measure of the responsive follicle pool, which helps guide the selection and customization of gonadotropin doses [2:24][3:15][14:3][15:4].
- Limitations: AFC is subject to inter-observer variability, and its accuracy can be influenced by operator experience and ultrasound resolution.
¶ Follicle-Stimulating Hormone (FSH) & Estradiol
Basal FSH and estradiol levels are measured during the early follicular phase of the menstrual cycle [2:25][22]. As the ovarian follicle pool declines, basal FSH levels typically exhibit a compensatory rise due to decreased negative feedback [2:26][22:1]. Early follicular estradiol must be co-evaluated, as elevated estradiol can artificially suppress FSH levels, potentially masking a decline in ovarian reserve [2:27][22:2].
¶ CRITICAL WARNING: Predictor of Yield vs. Fertility
CRITICAL CLINICAL REALITY
Ovarian reserve tests (such as AMH and AFC) must NOT be marketed or utilized as diagnostic markers of natural fertility, spontaneous conception, or time to menopause in fertile women [2:28][3:16][4:13]. Clinical guidelines and reviews emphasize that measures of ovarian reserve are poor predictors of reproductive potential and do not reflect a patient's probability of natural conception [2:29][3:17][4:14]. Ovarian reserve tests are strictly validated as predictors of oocyte yield following controlled ovarian stimulation and oocyte retrieval, helping clinicians customize stimulation protocols [2:30][3:18][4:15][14:4][15:5].
¶ Fertility Preservation Modalities
Modern assisted reproductive technology (ART) provides three primary established modalities to safeguard future reproductive potential [1:6][13:1].
¶ Oocyte Cryopreservation
Oocyte cryopreservation is the standard of care for single individuals opting for planned (elective) or medical fertility preservation [1:7][5:2].
- Controlled Ovarian Stimulation (COS): Exogenous gonadotropins are administered to induce multifollicular development in the ovaries [14:5][15:6].
- Retrieval: Transvaginal ultrasound-guided oocyte retrieval is performed surgically to harvest mature oocytes [2:31][4:16].
- Vitrification: Vitrification (ultra-rapid freezing) is the standard method for oocyte cryopreservation [8:3][9:4][10:1]. Large-scale clinical evaluations show that vitrification yields significantly higher post-thaw survival, fertilization, and pregnancy rates compared to traditional slow-freezing methods [8:4][9:5][10:2].
Figure 2: Standard Cryopreservation Methods. Vitrification has replaced slow-freezing as the clinical standard for preserving oocytes and embryos, resulting in superior post-thaw cellular survival and clinical success rates.
¶ Embryo Cryopreservation
Embryo cryopreservation is an established, highly successful modality for individuals with a committed partner or those utilizing donor sperm [1:8][11:1].
- Process: Retrieved oocytes are fertilized immediately via conventional IVF or Intracytoplasmic Sperm Injection (ICSI) [9:6]. The resulting embryos are cultured to the blastocyst stage (day 5 or 6) and vitrified [18:1][9:7].
- Considerations: Embryo vitrification has historically been associated with high post-thaw survival and clinical pregnancy rates [18:2][9:8]. Conversely, embryo cryopreservation requires fertilizing the oocytes prior to vitrification, which necessitates partner or donor sperm [1:9][11:2]. For patients without a partner or those who do not wish to use donor sperm, oocyte cryopreservation is the preferred alternative, preserving complete reproductive autonomy [1:10][11:3].
¶ Ovarian Tissue Cryopreservation (OTC)
Once classified as experimental, OTC is now an established standard clinical option, particularly for prepubertal females (for whom it is the only established method) or adult patients who cannot delay the initiation of gonadotoxic therapies for the 10 to 14 days required for standard ovarian stimulation [1:11][13:2].
- Procedure: Laparoscopic surgery is performed to excise the ovarian cortex (or an entire ovary), which contains a high density of primordial follicles [13:3]. The cortical tissue is processed into thin strips and vitrified [13:4].
- Replantation: Following remission, the cryopreserved ovarian tissue can be orthotopically transplanted back into the pelvis to restore ovarian endocrine function and facilitate future pregnancies [1:12][13:5][23].
- Outcomes: OTC is highly effective at restoring ovarian endocrine function and has resulted in numerous spontaneous and IVF-assisted live births [13:6][23:1].
¶ Controlled Ovarian Stimulation (COS) Risks & Management
Controlled ovarian stimulation (COS) and surgical oocyte retrieval are highly established clinical procedures in assisted reproductive technology, but they carry distinct clinical risks that require careful risk stratification, individualized dosing, and clinical mitigation [12:3][14:6][15:7][17:1].
¶ Ovarian Hyperstimulation Syndrome (OHSS)
Ovarian Hyperstimulation Syndrome (OHSS) is an iatrogenic complication of ovarian stimulation that can represent a serious clinical risk [14:7][15:8]. It is characterized by massive cystic enlargement of the ovaries and fluid shift from the intravascular space to third-space compartments (pleural cavity, peritoneum) due to increased vascular permeability driven by vasoactive factors (predominantly VEGF) [14:8][15:9].
¶ Risk Factors
- Biochemical and Biophysical Markers: The primary risk factor is a high baseline ovarian reserve, where expected high responders—typically characterized by elevated Anti-Müllerian Hormone (AMH) levels, high Antral Follicle Count (AFC), or polycystic ovarian morphology—are at the greatest risk [14:9][15:10].
- Peak Estradiol Levels: Highly elevated serum estradiol () levels or rapidly rising curves during controlled stimulation serve as key clinical predictors and risk factors for the development of severe OHSS [14:10][15:11].
¶ Mitigation and Prevention Strategies
- GnRH Antagonist Protocols: Utilizing a Gonadotropin-Releasing Hormone (GnRH) antagonist protocol for pituitary suppression is a cornerstone of OHSS prevention [16:1]. Unlike traditional long GnRH agonist flare or suppression protocols, antagonist protocols do not cause a flare effect and allow for alternative triggering methods [16:2].
- Agonist Trigger (GnRHa Trigger): In GnRH antagonist cycles, an agonist trigger (e.g., leuprolide acetate) is substituted for human chorionic gonadotropin (hCG) to induce the luteinizing hormone (LH) surge. Because the endogenous LH surge induced by GnRHa has a much shorter half-life than exogenous hCG, this approach prevents sustained luteal stimulation and virtually eliminates the risk of early-onset OHSS [16:3].
- ORT-Based Dosing Algorithms: Low-certainty evidence suggests that tailoring the starting gonadotropin dose utilizing ovarian reserve test (ORT) biomarkers (such as AMH and AFC) may reduce the incidence of moderate or severe OHSS compared to uniform standard dosing, although the precise clinical benefit and size of this effect remain unclear due to study limitations and variation in algorithms [14:11][15:12].
- Dose Customization: Adjusting and reducing the starting gonadotropin dose in expected high-responder cohorts minimizes OHSS risk without compromising overall cumulative live birth rates [14:12][15:13].
- Freeze-All Strategy: Implementing a "freeze-all" strategy by vitrifying all oocytes or embryos and deferring transfer to a subsequent, non-stimulated cycle is highly beneficial in high-responder cohorts to optimize live birth rates and prevent the late-onset OHSS triggered by endogenous hCG during pregnancy [18:3][14:13][15:14].
¶ Clinical Feasibility and Safety of Oocyte Retrieval
As a standard option for fertility preservation, oocyte retrieval requires careful clinical coordination and an individualized assessment of the patient's medical condition [12:4]. The feasibility and clinical safety of undergoing the retrieval procedure are dependent on multiple patient-specific factors, including the type of cancer, the urgency of initiating gonadotoxic treatments, the patient's age, and their overall systemic health [12:5]. For patients facing oncological emergencies or those with medical contraindications that preclude standard ovarian stimulation or retrieval, alternative options such as ovarian tissue cryopreservation or in vitro maturation may be indicated [12:6][1:13].
¶ Gonadotoxic Treatment & Medical Pathways
Oncofertility represents a crucial intersection between clinical oncology and reproductive medicine to optimize patient-centric quality of life post-remission [1:14][5:3][6:1].
¶ Gonadotoxic Pathways
Gonadotoxic cancer therapies—including chemotherapy, radiation, and surgical interventions—can significantly impair female reproductive potential and lead to treatment-induced ovarian dysfunction [24][12:7][21:1].
- Chemotherapy and Ovarian Dysfunction: Exposure to systemic chemotherapy can result in profound short- and long-term complications, including menstrual abnormalities, hot flashes, night sweats, impaired fertility, and premature ovarian insufficiency (POI) [21:2]. The clinical risk of developing ovarian dysfunction varies based on the specific drug classes received, the cumulative dosage, the number of treatment lines, the patient's baseline fertility status, and their age [21:3].
- Radiation and Surgery: Radiation therapies and surgical interventions can directly damage reproductive organs and impair future reproductive capacity [12:8]. Undergoing gonadotoxic treatments poses a direct threat of permanent follicular depletion, making early clinical counseling and referral crucial [12:9][1:15].
¶ Role of GnRH Agonists (Ovarian Suppression)
During chemotherapy, GnRH agonists may be administered to suppress the hypothalamic-pituitary-ovarian axis, putting the ovaries into a temporary suppressed state [1:16][5:4].
- Consensus & Guidelines: Clinical trial data has led to a strong consensus among major guidelines, including ASCO and NCCN [1:17][5:5]:
- GnRH agonists should NOT be used in place of established, proven fertility preservation methods (such as oocyte, embryo, or ovarian tissue cryopreservation) [1:18][5:6].
- They may be offered as an adjunct therapy during chemotherapy for young patients with breast cancer or other malignancies to reduce the risk of chemotherapy-induced POI and to provide menstrual suppression to prevent severe bleeding [1:19][5:7].
¶ Success Rates & Age-Specific Predictors
The clinical success of fertility preservation is a function of age at the time of retrieval and the quantity of vitrified gametes [18:4][7:7][2:32].
¶ Age-Specific Live Birth Rates
The clinical success of utilizing cryopreserved oocytes is highly age-dependent, with significantly superior outcomes observed when oocytes are retrieved and stored at a younger age [7:8].
A trinational registry cohort study by Johnston et al. (2021) analyzed demographic trends and documented a dramatic rise in oocyte cryopreservation cycles (+880% in the USA from 2010 to 2016 and +311% in Australia and New Zealand from 2010 to 2015), along with a shift toward younger cohorts undergoing storage [7:9]. However, the study also highlighted that the number of women returning to thaw their cryopreserved oocytes remains very low, representing a critical gap in long-term utilization data [7:10].
Registry data shows that age at retrieval significantly influences outcomes; specifically, thaw cycles started in women who stored oocytes when aged 35 or younger resulted in a 38% live birth rate, whereas only 16% resulted in a live birth for women who stored oocytes when aged 36 or older [7:11].
¶ Oocyte Quantity and Cumulative Probability
Clinicians must counsel patients that there are no guarantees of a future live birth, and that the probability of success is a cumulative function of the number of vitrified mature oocytes [7:12][2:33]. Generally, storing a larger number of mature oocytes increases the cumulative probability of at least one live birth, but older patients typically require a significantly larger number of retrieved oocytes to achieve comparable success rates due to advancing chronological age being the primary determinant of reproductive success [7:13][2:34].
¶ Freeze-All Embryo Strategy
In IVF cycles, registry data on 82,935 cycles from the Society for Assisted Reproductive Technology (SART) registry demonstrated that a "freeze-all" strategy (vitrifying all embryos and transferring them in a subsequent, non-stimulated cycle) is highly beneficial for specific patient cohorts [18:5]:
- High Responders ( oocytes): Freeze-all cycles yielded significantly higher clinical pregnancy rates and live birth rates (LBR) compared to fresh transfers (LBR: 52.0% vs. 48.9%) [18:6].
- Intermediate (6-14 oocytes) & Low (1-5 oocytes) Responders: Freeze-all offered no benefit and actually resulted in significantly lower live birth rates compared to fresh embryo transfers [18:7]. Specifically, intermediate responders had LBR of 41.2% after fresh ET vs. 35.3% after FET, while low responders had LBR of 25.9% after fresh ET vs. 11.5% after FET [18:8]. Therefore, the freeze-all strategy should be customized based on individual response rather than applied universally [18:9].
¶ Access Inequities & Disparities
Retrieval and utilization of fertility preservation are characterized by pronounced socioeconomic, geographic, and racial disparities [25][24:1].
- Disparities in Cancer Patients: Despite ASCO guidelines recommending universal counseling and referral, population-based registry data shows that only 1.2% of adolescent and young adult (AYA) women diagnosed with cancer utilize fertility preservation [25:1].
- Demographic Disparities: Women significantly less likely to utilize fertility preservation include those who were older at diagnosis, non-Hispanic Black (Prevalence Ratio = 0.44), parous at diagnosis (PR = 0.24), living in non-urban areas (PR = 0.12), or residing in census tracts of lower socioeconomic status (PR = 0.39) [25:2].
- Geographic and Guideline Implementation Gaps: A survey of major pediatric oncology centers in the Nordic-Baltic region demonstrated that only 65% of centers had national guidelines on fertility preservation [24:2]. Furthermore, counseling was unavailable for many patients due to age-related restrictions (35%), communication issues (29%), or a lack of clinical time (24%) [24:3]. These findings highlight the critical need to standardize clinical indications and widely disseminate guidelines to reduce clinical variability and ensure equitable access [24:4].
¶ Socioeconomic, Logistical, & Access Issues
The clinical implementation of fertility preservation involves significant socioeconomic, geographic, and logistical barriers that affect patient counseling, referral, and treatment utilization [25:3][24:5][12:10][1:20].
¶ Logistical & Financial Barriers to Fertility Preservation
While clinical guidelines strongly recommend early counseling and referral for fertility preservation, patients face significant financial, geographic, and systemic barriers to accessing care [25:4][24:6][12:11][26].
- Socioeconomic and Insurance Barriers: The substantial out-of-pocket costs of ovarian stimulation medications, clinical monitoring, and long-term storage represent a major barrier to care [12:12][26:1]. Studies show that states with legislatively mandated insurance coverage for fertility preservation have significantly higher rates of clinical counseling and referral compared to states without legislation [27]. Financial cost is the most commonly reported barrier to counseling among pediatric oncology providers [26:2].
- Geographic and Demographic Disparities: Population-based registry data demonstrates that only 1.2% of adolescent and young adult (AYA) women with cancer utilize fertility preservation [25:5]. Women less likely to utilize these services include those living in non-urban areas (Prevalence Ratio = 0.12), those of lower socioeconomic status, and Black women [25:6].
- Clinical Guidelines Implementation Gaps: Survey data indicates that even in major centers, only 65% have national guidelines on fertility preservation, and counseling is often omitted due to communication barriers, age restrictions, or limited clinic time [24:7]. Standardizing clinical indications and widely disseminating guidelines are crucial to reduce clinical variability and ensure equitable access [24:8].
- Clinical Coordination and Training Gaps: Ensuring prompt access to a multidisciplinary fertility preservation team is essential [1:21]. However, barriers such as communication issues, limited institutional collaboration, and unclear risk stratification continue to hinder timely referrals [24:9][12:13]. Furthermore, oncology teams frequently report a lack of specialized oncofertility training, which can limit the depth of fertility counseling [1:22][28].
¶ Evidence Limits of Ovarian Rejuvenation & Supplement Claims
In response to the natural decline of ovarian reserve, several experimental clinical interventions have emerged, marketed under the umbrella of "ovarian rejuvenation," primarily utilizing intraovarian platelet-rich plasma (PRP) injections [29][30][31][32]. Clinicians must counsel patients that these therapies are considered highly experimental, lack high-quality clinical validation, and have very-low-certainty evidence bases [29:1][30:1][32:1]. Major clinical consensus guidelines for fertility preservation (such as ASCO, ESHRE, or ASRM) recommend only established techniques—such as oocyte, embryo, or ovarian tissue cryopreservation—and do not recommend or support experimental ovarian rejuvenation procedures [1:23][2:35][11:4][13:7][23:2].
While some pilot studies and systematic reviews of small, heterogeneous trials suggest that autologous PRP injections may associate with improvements in surrogate biochemical markers (such as FSH, AMH, and estradiol) or oocyte/embryo yield [33][30:2][31:1][34][35], there are currently no large-scale, high-quality, sham-controlled randomized controlled trials (RCTs) demonstrating that these interventions improve clinical pregnancy rates or live birth rates in patients with diminished ovarian reserve (DOR) or premature ovarian insufficiency (POI) [29:2][33:1][30:3][32:2]. Similarly, although meta-analyses of small trials indicate that oral nutritional supplements (including coenzyme Q10 and dehydroepiandrosterone [DHEA]) may support minor improvements in ovarian stimulation outcomes and surrogate markers [36], they lack robust clinical validation for improving live birth rates [36:1]. Clinicians must advise patients that these alternative options lack rigorous clinical validation and are not recommended for routine clinical use to preserve or restore fertility [36:2][29:3][30:4][32:3].
¶ Evidence Summary Table (Human Outcomes)
The major clinical interventions utilized to assess and preserve reproductive potential are evaluated below based on current clinical evidence.
| Outcome / Goal | Effect* | Consistency | Evidence Quality | Trials | Notes (population, duration, dose) |
|---|---|---|---|---|---|
| Oocyte Vitrification (LBR for age ) | High | High | 10+ Cohorts / SART Registries | Yields cumulative live birth rates; highly dependent on storing a sufficient cohort of mature oocytes [7:14][2:36]. | |
| Oocyte Vitrification (LBR for age ) | High | High | 10+ Cohorts / SART Registries | Sharp decline in live birth rate per thaw cycle due to advanced chronological age and baseline rate of oocyte aneuploidy [7:15][2:37]. | |
| Embryo Vitrification (Post-thaw LBR for High Responders) | High | High | 15+ Registries / RCTs | Highly established; freeze-all strategy beneficial in high responders, yielding higher live birth rates [18:10]. | |
| Ovarian Tissue Cryopreservation (OTC) | High | Moderate | 8+ Cohorts / Guidelines | Restores ovarian endocrine function post-transplant; standard for prepubertal and urgent medical cases [13:8][23:3]. | |
| GnRH Agonist Ovarian Suppression | Moderate | Moderate | 12+ RCTs | Recommended only as an adjunct during chemotherapy for breast cancer to reduce POI risk, not as a replacement for cryopreservation [1:24][5:8][11:5]. | |
| Fertility Preservation Counseling (AYA Cancer Patients) | High | High | 1 Cohort / Registry | Extremely low utilization rate (1.2%) despite clear clinical consensus and ASCO guideline recommendations [25:7]. | |
| Sperm Cryopreservation | High | High | 15+ Registries / Guidelines | Highly established, standard method to preserve reproductive potential in post-pubertal males [1:25][5:9][11:6]. |
¶ FAQ
¶ Does a low Anti-Müllerian Hormone (AMH) level mean that a patient is currently infertile?
No. AMH is utilized clinically as an indirect measure of ovarian reserve to estimate expected oocyte yield during controlled ovarian stimulation and to customize starting gonadotropin doses [2:38][3:19][4:17]. However, because AMH exclusively measures follicle quantity and does not reflect oocyte quality (which is strictly age-dependent), it is a poor predictor of natural reproductive potential and should not be used as a standalone fertility test to predict the likelihood of spontaneous, unassisted conception [2:39]. In young patients, a low AMH does not indicate subfertility, as oocyte quality remains high and is primarily driven by their young chronological age [7:16][2:40].
¶ Is embryo freezing superior to oocyte freezing for fertility preservation?
Both embryo and oocyte cryopreservation are standard, highly effective clinical options for preserving reproductive potential [1:26][11:7]. While embryo freezing has historically been associated with high post-thaw success, it requires fertilizing the oocytes with partner or donor sperm [9:9]. Oocyte freezing avoids these interpersonal requirements, preserving complete reproductive autonomy for the individual [1:27][11:8].
¶ How many frozen oocytes are required to provide a reasonable chance of a future live birth?
The cumulative probability of achieving a future live birth depends heavily on both the total number of vitrified mature oocytes and the patient's age at the time of retrieval [7:17][2:41]. Because oocyte quality is strictly age-dependent, younger patients have significantly higher live birth rates per thawed oocyte [7:18]. Specifically, registry data shows that thaw cycles in women who stored oocytes when aged 35 or younger resulted in a 38% live birth rate, whereas only 16% resulted in a live birth for women who stored oocytes when aged 36 or older [7:19]. Older patients typically require a significantly larger number of retrieved oocytes to achieve comparable success rates [7:20][2:42].
¶ Can cancer patients safely undergo ovarian stimulation without delaying their oncological treatments?
In many clinical scenarios, standard fertility preservation can be safely performed prior to initiating gonadotoxic therapies [1:28][21:4]. However, because the feasibility, safety, and timing of controlled ovarian stimulation depend heavily on the type of cancer, treatment urgency, patient age, and overall medical condition, early referral and rapid, multidisciplinary coordination between oncology and reproductive teams are essential [1:29][21:5]. For patients who cannot undergo stimulation due to urgent oncological timelines, alternative options such as ovarian tissue cryopreservation may be utilized [13:9][23:4].
¶ What is Ovarian Tissue Cryopreservation (OTC), and who is it intended for?
OTC is an established standard clinical option involving the surgical removal and vitrification of outer ovarian cortex tissue, which contains a dense population of primordial follicles [1:30][13:10]. It is the only option for prepubertal girls facing gonadotoxic treatments (as they cannot undergo ovarian stimulation) and for adult patients who cannot delay their chemotherapy by 10 to 14 days to undergo a standard oocyte retrieval cycle [1:31][13:11][23:5]. Post-remission, the tissue is autotransplanted back into the patient, where it restores ovarian endocrine function and has led to spontaneous and IVF-assisted pregnancies [13:12][23:6].
¶ References
Su HI, Lacchetti C, Letourneau J, et al. Fertility Preservation in People With Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43. https://pubmed.ncbi.nlm.nih.gov/40106739/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and Sterility. 2020;114(6):1151-1157. https://pubmed.ncbi.nlm.nih.gov/33280722/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Baker KM, FernandezCriado R, Eaton JL. The Clinical Utility of Measures of Ovarian Reserve. Obstetrical & Gynecological Survey. 2025;80(2):83-93. https://pubmed.ncbi.nlm.nih.gov/39924338/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Cedars MI. Evaluation of Female Fertility-AMH and Ovarian Reserve Testing. The Journal of Clinical Endocrinology and Metabolism. 2022;107(6):1510-1519. https://pubmed.ncbi.nlm.nih.gov/35100616/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 2018;36(19):1994-2001. https://pubmed.ncbi.nlm.nih.gov/29620997/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Oktay K, Harvey BE, Loren AW, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary. Journal of Oncology Practice. 2018;14(6):381-385. https://pubmed.ncbi.nlm.nih.gov/29768110/ ↩︎ ↩︎
Johnston M, Richings NM, Leung A. A major increase in oocyte cryopreservation cycles in the USA, Australia and New Zealand since 2010 is highlighted by younger women but a need for standardized data collection. Human Reproduction. 2021;36(3):696-702. https://pubmed.ncbi.nlm.nih.gov/33367704/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Chen SU, Yang YS. Slow freezing or vitrification of oocytes: their effects on survival and meiotic spindles, and the time schedule for clinical practice. Taiwanese Journal of Obstetrics & Gynecology. 2009;48(1):15-22. https://pubmed.ncbi.nlm.nih.gov/19346187/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Simopoulou M, Asimakopoulos B, Bakas P. Oocyte and embryo vitrification in the IVF laboratory: a comprehensive review. Folia Medica. 2014;56(3):149-158. https://pubmed.ncbi.nlm.nih.gov/25434072/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Levi-Setti PE, Patrizio P, Scaravelli G. Evolution of human oocyte cryopreservation: slow freezing versus vitrification. Current Opinion in Endocrinology, Diabetes, and Obesity. 2016;23(6):445-450. https://pubmed.ncbi.nlm.nih.gov/27653002/ ↩︎ ↩︎ ↩︎
Bhinder JK, Peera M, Al-Khaifi M. Comparison of Fertility-Related Recommendations Across National Comprehensive Cancer Network, ASCO, Clinical Oncology Society of Australia, and European Society for Medical Oncology Guidelines for People With Cancer Comparing Fertility Recommendations for People With Cancer. JCO Oncology Practice. 2026. https://pubmed.ncbi.nlm.nih.gov/41534015/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kalluru S, Vu M, Brady PC. Fertility preservation for cancer: referral guidelines, treatment options, and specific considerations. Fertility and Sterility. 2025. https://pubmed.ncbi.nlm.nih.gov/40854469/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Martinez F. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Human Reproduction. 2017;32(9):1802-1811. https://pubmed.ncbi.nlm.nih.gov/29117320/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ngwenya O, Lensen SF, Vail A. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). The Cochrane Database of Systematic Reviews. 2024;1(1):CD010976. https://pubmed.ncbi.nlm.nih.gov/38174816/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Lensen SF, Wilkinson J, Leijdekkers JA, et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). The Cochrane Database of Systematic Reviews. 2018;2(2):CD010976. https://pubmed.ncbi.nlm.nih.gov/29388198/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
The ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Human Reproduction Open. 2020;2020(2):hoaa009. https://pubmed.ncbi.nlm.nih.gov/32395637/ ↩︎ ↩︎ ↩︎ ↩︎
Haahr T, Esteves SC, Humaidan P. Individualized controlled ovarian stimulation in expected poor-responders: an update. Reproductive Biology and Endocrinology. 2018;16(1):17. https://pubmed.ncbi.nlm.nih.gov/29523204/ ↩︎ ↩︎
Acharya KS, Acharya CR, Bishop K. Freezing of all embryos in in vitro fertilization is beneficial in high responders, but not intermediate and low responders: an analysis of 82,935 cycles from the Society for Assisted Reproductive Technology registry. Fertility and Sterility. 2018;110(3):430-437. https://pubmed.ncbi.nlm.nih.gov/30139718/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Pastore LM, Johnson J. The FMR1 gene, infertility, and reproductive decision-making: a review. Frontiers in Genetics. 2014;5:248. https://pubmed.ncbi.nlm.nih.gov/25071825/ ↩︎
Blaauwendraad SM, Dykgraaf RHM, Gaillard R. Associations of bisphenol and phthalate exposure and anti-Müllerian hormone levels in women of reproductive age. EClinicalMedicine. 2024;74:102714. https://pubmed.ncbi.nlm.nih.gov/39114272/ ↩︎ ↩︎
Reynolds AC, McKenzie LJ. Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options. Journal of Clinical Oncology. 2023;41(12):2284-2294. https://pubmed.ncbi.nlm.nih.gov/36888938/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Maseelall PB, McGovern PG. Ovarian reserve screening: what the general gynecologist should know. Women's Health. 2008;4(3):281-291. https://pubmed.ncbi.nlm.nih.gov/19072478/ ↩︎ ↩︎ ↩︎
Martinez F, International Society for Fertility Preservation–ESHRE–ASRM Expert Working Group. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Fertility and Sterility. 2017;108(3):407-415. https://pubmed.ncbi.nlm.nih.gov/28739117/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Grubliauskaite M, Gudleviciene Z, Oskam IC, et al. Guidelines, Counseling Practices, and Fertility Preservation Options for Childhood Cancer Patients in the Nordic-Baltic Region. JCO Oncology Practice. 2025. https://pubmed.ncbi.nlm.nih.gov/40184573/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Meernik C, Engel SM, Wardell A, et al. Disparities in fertility preservation use among adolescent and young adult women with cancer. Journal of Cancer Survivorship. 2023;17. https://pubmed.ncbi.nlm.nih.gov/35169982/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Campbell JE, Assanasen C, Robinson RD. Fertility preservation counseling for pediatric and adolescent cancer patients. Journal of Adolescent and Young Adult Oncology. 2016;5(1):58-63. https://pubmed.ncbi.nlm.nih.gov/26812454/ ↩︎ ↩︎ ↩︎
Patel P, Kohn TP, Cohen J. Evaluation of Reported Fertility Preservation Counseling Before Chemotherapy Using the Quality Oncology Practice Initiative Survey. JAMA Network Open. 2020;3(7):e2010831. https://pubmed.ncbi.nlm.nih.gov/32678451/ ↩︎
Stal J, Yi SY, Roche CI. Are guidelines guiding? A mixed methods study examining the integration of ASCO fertility discussion guidelines in practice among oncologists and adolescents and young adults at an NCI-designated Comprehensive Cancer Center. Journal of Cancer Survivorship. 2025. https://pubmed.ncbi.nlm.nih.gov/40536662/ ↩︎
Ahmadi F, Gharaei R, Shirali E. The impact of platelet-rich plasma (PRP) on ovarian function and oocyte quality: A comprehensive review. Journal of Reproductive Immunology. 2025;161. https://pubmed.ncbi.nlm.nih.gov/41033010/ ↩︎ ↩︎ ↩︎ ↩︎
Hu M, Tang L, Chen Y. Progress in research on the effects of Platelet-Rich Plasma (PRP) ovarian injection on early ovarian reserve dysfunction and premature ovarian insufficiency. Journal of Ovarian Research. 2026;19. https://pubmed.ncbi.nlm.nih.gov/41807979/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Merhi Z, Wiltshire McLeod C, Shamim F. Platelet-Rich Plasma in Reproductive Endocrinology: Mechanisms and Clinical Applications for Ovarian Reserve, PCOS, and Endometrial Receptivity. Biomedicines. 2025;13(10). https://pubmed.ncbi.nlm.nih.gov/41153771/ ↩︎ ↩︎
Loverro G, DI Naro E, Loverro M. Intraovarian injection of autologous platelet-rich-plasma: myth or reality? Minerva Obstetrics and Gynecology. 2025;77(3). https://pubmed.ncbi.nlm.nih.gov/39388219/ ↩︎ ↩︎ ↩︎ ↩︎
Li X, Liu H, Lin G. The effect of ovarian injection of autologous platelet rich plasma in patients with poor ovarian responder: a systematic review and meta-analysis. Frontiers in Endocrinology. 2023;14. https://pubmed.ncbi.nlm.nih.gov/38155954/ ↩︎ ↩︎
Navali N, Sadeghi L, Farzadi L. Intraovarian Injection of Autologous Platelet-Rich Plasma Improves Therapeutic Approaches in The Patients with Poor Ovarian Response: A Before-After Study. International Journal of Fertility & Sterility. 2022;16(2). https://pubmed.ncbi.nlm.nih.gov/35639652/ ↩︎
Garavelas A, Mallis P, Michalopoulos E. Clinical Benefit of Autologous Platelet-Rich Plasma Infusion in Ovarian Function Rejuvenation: Evidence from a Before-After Prospective Pilot Study. Medicines. 2023;10(3). https://pubmed.ncbi.nlm.nih.gov/36976308/ ↩︎
Li X, Zhao Q, Lin G. The auxiliary effect of oral nutritional supplements on fertility in women with diminished ovarian reserve: a systematic review and meta-analysis. Annals of Medicine. 2025;57(1). https://pubmed.ncbi.nlm.nih.gov/41185971/ ↩︎ ↩︎ ↩︎